MERGE microbial strain improvement technique

MERGE uses non-GMO techniques to turn probiotics into therapeutics and reliable, commercial strains

MERGE is a patented strain improvement technique which used a type of directed evolution resulting in new phenotypes and antimicrobials. It turns mediocre results into repeatable and reliable results.

SciBac has used MERGE to create 2 novel lung therapeutics with multiple mechanisms designed to clear chronic lung infections in cystic fibrosis.

  • Infection prevention
  • Antimicrobial stewardship
  • Alternative antimicrobials
  • Microbial diagnostics
  • Antimicrobial compound/strategy
  • Removal antibiotics/bacteria

  • Bacteria
  • Fungi
  • Yeasts
  • Parasites
  • Viruses

  • Human
  • Veterinary
  • AgriFood
  • Environmental
  • Other

Development stage:
  • Research
  • Development
  • Validation
  • Market entry
  • Marketed product

  • Company
  • Academia
  • Institute
  • NGO
  • Government

  • License
  • Co-develop
  • Joint Venture
  • Sell
  • Outsource

Funding organisation:

    Infectious disease area:

      Geographic origin:

        We are looking for partners to develop our lung therapeutics or to make novel ones with MERGE.

        We are a pre-clinical, biotech start-up. We have raised $2M and looking for additional revenue through out-licensing as well as angel investments.

        SciBac is open to improving existing biotherapeutics or creating new ones. We can use our technology to go after AMR anywhere there is a microbiome, so skin, uro-genital, lung, mouth, and gastro-intestinal applications can all be addressed.

        What is going on with AMR?
        Stay tuned with remarkable global AMR news and developments!